Curevac N.V. Stock
Price
Target price
€4.58
€4.58
-0.480%
-0.022
-0.480%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Curevac
sharewise wants to provide you with the best news and tools for Curevac, so we directly link to the best financial data sources.
Financials
News
CureVac Stock: BioNTech's Billion-Dollar Takeover Bid
The biotech landscape was shaken Thursday as BioNTech announced a takeover offer for Tübingen-based CureVac, valuing the company at approximately $1.25 billion (€1.08 billion). Under the proposed
CureVac Stock: Recovery Continues Despite Weekly Fluctuations
CureVac shares showed mixed performance in recent trading, hovering around the €2.80 mark with slight losses predominating. The stock slipped 1.1 percent to €2.78 on Friday morning, continuing
CureVac Stock: Shares Dip Despite Strong Revenue Surge
CureVac's stock experienced a notable decline on the trading day, settling at €3.40 on Tradegate, marking a 1.2 percent decrease. This downward movement comes as a surprise considering the company's
EQS-News: CureVac Announces Voting Results of General Meeting
EQS-News: CureVac Announces Voting Results of General Meeting
EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
EQS-News: CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
EQS-News: CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
EQS-News: CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
EQS-News: CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
EQS-News: CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
EQS-News: CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators
EQS-News: CureVac Earns Repeat Recognition by LexisNexis® as One of the World’s Top Innovators